Physician profile
Danielle D Buda
NPI 1205944949
$5,183.84
in general payments reported to CMS, 2019-2025
15 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $40.24 · 2021: $308 · 2022: $562 · 2023: $1,097 · 2024: $1,179 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,484.33 | 2021-2025 | Vraylar |
| Lundbeck LLC | $671.05 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $477.30 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $451.66 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $244.50 | 2019-2025 | Invega Sustenna, Spravato |
| Allergan, INC. | $235.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.58 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $123.09 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $98.72 | 2022-2024 | Adzenys Xr-Odt |
| Azurity Pharmaceuticals, INC. | $60.72 | 2023-2024 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $50.19 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $39.41 | 2019 | |
| Alkermes, INC. | $28.51 | 2021-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $18.10 | 2019 | |
| Bausch Health US, LLC | $13.94 | 2023 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Buda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.